Glaukos Corp GKOS

Glaukos (GKOS) slipped about 1% at the last close to $159.86, extending a month-long pullback of roughly 14%, even as the ophthalmic specialist posts annual revenue of $612.8 million. Glaukos shares have cooled off in the short term, with a 7 day share price return down 6.9% and a 30 day share price return down 13.5%. The broader trend is still strong, as the year to date share price return sits at 44.4% and the 1 year total shareholder return is 88.8%, which may indicate that recent weakness...

Investor's Business Daily's IBD 50 index is on track for a third straight down month, and some of its components are sputtering. Various factors help decide when to sell stocks, and five have already triggered sell signals. AngloGold Ashanti broke out above a 113.30 buy point on Aug. 20.

ALISO VIEJO, Calif., August 19, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA.

As the market rallies, Raymond James, Tapestry and U.S. Bancorp lead a slew of stocks to watch in or near buy range.

Glaukos (GKOS) just reported record second quarter sales and raised its 2026 net sales guidance to a range of $680 million to $700 million, putting fresh attention on the stock. See our latest analysis for Glaukos. The raised 2026 guidance and record quarter have come alongside sharp share price momentum, with Glaukos posting a 20.6% 1 month share price return and a 52.2% year to date share price return, contributing to a 95.8% 1 year total shareholder return. If this kind of move has your...

In late July 2026, Glaukos Corporation reported record second-quarter results, with net sales rising to US$185.61 million and a narrower quarterly loss, and raised its 2026 net sales guidance to US$680 million–US$700 million from US$620 million–US$635 million. Alongside the guidance increase, Glaukos completed enrollment in its pivotal U.S. PRESERFLO MicroShunt study, underscoring how expanding clinical programs and strong uptake of products like iDose TR and Epioxa are shaping expectations...